HTG Molecular Diagnostics Future Growth
Future criteria checks 2/6
HTG Molecular Diagnostics is forecast to grow earnings and revenue by 32.8% and 34.2% per annum respectively while EPS is expected to grow by 108.3% per annum.
Key information
32.8%
Earnings growth rate
108.3%
EPS growth rate
Healthcare Services earnings growth | 29.1% |
Revenue growth rate | 34.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Mar 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 10 | -14 | N/A | N/A | 1 |
12/31/2022 | 6 | -21 | N/A | N/A | 1 |
9/30/2022 | 7 | -22 | -20 | -20 | N/A |
6/30/2022 | 8 | -22 | -20 | -19 | N/A |
3/31/2022 | 9 | -19 | -19 | -18 | N/A |
12/31/2021 | 9 | -17 | -17 | -17 | N/A |
9/30/2021 | 9 | -16 | -17 | -17 | N/A |
6/30/2021 | 8 | -17 | -17 | -17 | N/A |
3/31/2021 | 8 | -20 | -17 | -17 | N/A |
12/31/2020 | 9 | -21 | -17 | -16 | N/A |
9/30/2020 | 11 | -21 | -17 | -17 | N/A |
6/30/2020 | 14 | -20 | -17 | -16 | N/A |
3/31/2020 | 18 | -19 | -16 | -15 | N/A |
12/31/2019 | 19 | -19 | -18 | -17 | N/A |
9/30/2019 | 22 | -17 | -16 | -15 | N/A |
6/30/2019 | 21 | -17 | -15 | -15 | N/A |
3/31/2019 | 21 | -16 | -17 | -16 | N/A |
12/31/2018 | 22 | -16 | -14 | -13 | N/A |
9/30/2018 | 22 | -16 | -15 | -13 | N/A |
6/30/2018 | 21 | -17 | -16 | -14 | N/A |
3/31/2018 | 18 | -19 | -16 | -15 | N/A |
12/31/2017 | 15 | -19 | -18 | -17 | N/A |
9/30/2017 | 8 | -23 | -19 | -19 | N/A |
6/30/2017 | 6 | -24 | -19 | -19 | N/A |
3/31/2017 | 6 | -25 | -23 | -21 | N/A |
12/31/2016 | 5 | -26 | -24 | -22 | N/A |
9/30/2016 | 5 | -26 | -24 | -22 | N/A |
6/30/2016 | 5 | -25 | N/A | -22 | N/A |
3/31/2016 | 4 | -25 | N/A | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 65H is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 65H is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 65H is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 65H's revenue (34.2% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 65H's revenue (34.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 65H's Return on Equity is forecast to be high in 3 years time